Payment overview · 2025
General Payments
$1,008.60
71 reported records · 15 companies
Healthcare provider profile · identity verified
Carmelo Cabalu Mendiola, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FORT PAYNE, AL · NPI 1023063922
Verified facts
What the public records show
CMS Open Payments records show Carmelo Cabalu Mendiola, MD received $1,008.60 in general payments during 2025 across 71 reported records.
OPKO Pharmaceuticals, LLC accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rayaldee, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Rayaldee by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 409 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $270.41 | 26.8% | 32 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $246.09 | 24.4% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $162.83 | 16.1% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.39 | 6.3% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.15 | 3.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.86 | 3.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.37 | 2.8% | 1 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $25.81 | 2.6% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $24.20 | 2.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.25 | 2.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.02 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.77 | 2.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.47 | 2.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.35 | 2.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.63 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $948.01 | 64 |
| Education | $60.59 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $270.41 | 32 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $246.09 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.48 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $42.64 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.05 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.86 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.86 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.44 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $28.37 | 1 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $3.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 409 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 194 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 235 | exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 231 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
89 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
90 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
194 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
86 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
235 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
231 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
409 | 71 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1002 | 274 |
| Levothyroxine Sodium | Levothyroxine Sodium | 896 | 209 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 881 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 822 | 219 |
| Gabapentin | Gabapentin | 776 | 137 |
| Omeprazole | Omeprazole | 662 | 174 |
| Pantoprazole Sodium | Pantoprazole Sodium | 633 | 167 |
| Carvedilol | Carvedilol | 608 | 157 |
| Lisinopril | Lisinopril | 555 | 136 |
| Clonazepam | Clonazepam | 545 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 544 | 148 |
| Metformin Hcl | Metformin Hcl | 532 | 141 |
| Losartan Potassium | Losartan Potassium | 518 | 137 |
| Eliquis | Apixaban | 409 | 71 |
| Calcitriol | Calcitriol | 394 | 105 |
| Furosemide | Furosemide | 338 | 104 |
| Trazodone Hcl | Trazodone Hcl | 323 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 308 | 95 |
| Glimepiride | Glimepiride | 305 | 87 |
| Tramadol Hcl | Tramadol Hcl | 265 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 260 | 74 |
| Alendronate Sodium | Alendronate Sodium | 255 | 75 |
| Buspirone Hcl | Buspirone Hcl | 254 | 56 |
| Montelukast Sodium | Montelukast Sodium | 249 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 247 | 61 |
| Ozempic | Semaglutide | 235 | 48 |
| Mirtazapine | Mirtazapine | 234 | 50 |
| Rayaldee | Calcifediol | 231 | 28 |
| Cefdinir | Cefdinir | 230 | 184 |
| Allopurinol | Allopurinol | 226 | 63 |
| Simvastatin | Simvastatin | 221 | 58 |
| Baclofen | Baclofen | 204 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 48 |
| Ezetimibe | Ezetimibe | 194 | 53 |
| Mounjaro | Tirzepatide | 194 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 193 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 52 |
| Potassium Chloride | Potassium Chloride | 186 | 46 |
| Prednisone | Prednisone | 186 | 119 |
| Zolpidem Tartrate | Zolpidem Tartrate | 186 | 25 |
| Meloxicam | Meloxicam | 182 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 180 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 180 | 44 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 179 | 132 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 177 | 48 |
| Temazepam | Temazepam | 173 | 23 |
| Lorazepam | Lorazepam | 170 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 50 |
| Alprazolam | Alprazolam | 164 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 161 | 44 |
| Sertraline Hcl | Sertraline Hcl | 157 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 155 | 22 |
| Valsartan | Valsartan | 154 | 40 |
| Ropinirole Hcl | Ropinirole Hcl | 146 | 33 |
| Finasteride | Finasteride | 143 | 41 |
| Pregabalin | Pregabalin | 138 | 26 |
| Sucralfate | Sucralfate | 138 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 138 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 34 |
| Nabumetone | Nabumetone | 118 | 29 |
| Synthroid | Levothyroxine Sodium | 117 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 35 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 112 | 88 |
| Jardiance | Empagliflozin | 108 | 20 |
| Estradiol | Estradiol | 107 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 31 |
| Ramipril | Ramipril | 102 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 99 | 19 |
| Clindamycin Hcl | Clindamycin Hcl | 97 | 71 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 93 | 21 |
| Famotidine | Famotidine | 90 | 25 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 90 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 89 | 19 |
| Farxiga | Dapagliflozin Propanediol | 89 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 19 |
| Linzess | Linaclotide | 88 | 25 |
| Azithromycin | Azithromycin | 87 | 71 |
| Benazepril Hcl | Benazepril Hcl | 87 | 26 |
| Trulicity | Dulaglutide | 86 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 19 |
| Fenofibrate | Fenofibrate | 84 | 26 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 84 | suppressed |
| Glipizide | Glipizide | 82 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 79 | 14 |
| Warfarin Sodium | Warfarin Sodium | 78 | 16 |
| Fentanyl | Fentanyl | 73 | suppressed |
| Atenolol | Atenolol | 72 | 18 |
| Levofloxacin | Levofloxacin | 72 | 62 |
| Sevelamer Carbonate | Sevelamer Carbonate | 70 | 20 |
| Donepezil Hcl | Donepezil Hcl | 68 | 21 |
| Ondansetron Odt | Ondansetron | 67 | 50 |
| Topiramate | Topiramate | 67 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 64 | 15 |
| Januvia | Sitagliptin Phosphate | 62 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 16 |
| Repatha Sureclick | Evolocumab | 59 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 58 | suppressed |
| Levetiracetam | Levetiracetam | 57 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 15 |
| Venlafaxine Hcl | Venlafaxine Hcl | 56 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 55 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 54 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | suppressed |
| Amoxicillin | Amoxicillin | 53 | 41 |
| Clonidine Hcl | Clonidine Hcl | 52 | 16 |
| Diazepam | Diazepam | 52 | suppressed |
| Fluconazole | Fluconazole | 51 | 34 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 50 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 49 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | suppressed |
| Lovastatin | Lovastatin | 49 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 16 |
| Enalapril Maleate | Enalapril Maleate | 48 | suppressed |
| Memantine Hcl | Memantine Hcl | 47 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 47 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 47 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | suppressed |
| Celecoxib | Celecoxib | 45 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 44 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 33 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 43 | suppressed |
| Methocarbamol | Methocarbamol | 43 | 12 |
| Spironolactone | Spironolactone | 42 | 14 |
| Midodrine Hcl | Midodrine Hcl | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 12 |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 38 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 38 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 21 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 21 |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 31 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 31 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 13 |
| Ibuprofen | Ibuprofen | 26 | 11 |
| Livalo | Pitavastatin Calcium | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | 15 |
| Dutasteride | Dutasteride | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 25 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 24 | suppressed |
| Jantoven | Warfarin Sodium | 24 | suppressed |
| Nystatin | Nystatin | 24 | 15 |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Calcium Acetate | Calcium Acetate | 22 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 12 |
| Metronidazole | Metronidazole | 21 | 11 |
| Bumetanide | Bumetanide | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Niacin Er | Niacin | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Oxazepam | Oxazepam | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,008.60 · 71 records | OPKO Pharmaceuticals, LLC | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, GEMTESA, JYNARQUE, LOREEV XR, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, RAYALDEE, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VERQUVO, Vafseo, Wegovy, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error